M Pharmaceutical Inc.
CNSX : MQ
OTCQB : MPHMF
FRANKFURT : T3F2

M Pharmaceutical Inc.

June 27, 2016 16:15 ET

M Pharmaceutical Closed Over-Subscribed Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 27, 2016) -

NOT FOR RELEASE IN THE UNITED STATES

M Pharmaceutical, Inc. (CSE:MQ) (OTCQB:MPHMF) (FRANKFURT:T3F2 ), (the "Company" or "M Pharma"), announced that it has closed its previously announced private placement on an over-subscribed basis. The Company has issued 34,433,179 units at $0.025 per unit for gross proceeds of $860,829.47. Each unit consists of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant") entitling the holder to purchase one additional Common Share for $0.05 for a period of 12 months. Proceeds will be used for the US $200,000 payment due on the closing of the Chelatexx acquisition, working capital and paying down debt. Securities issued hereunder will be subject to trading restrictions until October 28, 2016.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to the intended acquisition of C-103 from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the its biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Contact Information